Fig. 1From: Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agentBinding and Energetics Analysis of Dexamethasone against SARS-CoV-2 RBD. A, Distribution of dexamethasone binding preferences against the strains of SARS-CoV-2. B, Two-dimensional representation of Dexamethasone interaction against the SARS-CoV-2 RBDs of Wild type, variant Omicron, BJ.1, BM.1.1.1, XBB and XBB.1.5, respectivelyBack to article page